ArticleInternational journal of radiation oncology, biology, physics2025
High-Dose-Rate Brachytherapy for Vaginal Rhabdomyosarcoma (RMS): Lessons Learned at a Single Institution.
Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBotryoid rhabdomyosarcoma (RMS) arises within the vaginal wall of young girls. Most patients are classified as low- or intermediate-risk and treated with limited-intensity chemotherapy, but local treatment is required to minimize the risk of local relapse. Intravaginal brachytherapy (IVRT) may be an effective local therapy that minimizes sequelae in young patients. METHODS AND MATERIALS: We reviewed the records of all patients with RMS who received high-dose-rate IVRT from 2010 to 2024 at a single institution. All received multiagent chemotherapy with or without conservative surgical procedures to resect gross residual disease. All patients underwent computed tomography simulation under anesthesia and cylindrical applicators were used. Descriptive statistics and Kaplan-Meier analysis were used to evaluate the cohort, local control, and overall survival.
resultsTwelve patients (median age 23 months [range, 8-33]), were identified. All were in stage 1 and 92% had group III disease. The first 5 patients received 2100 cGy in 7 fractions; subsequent patients received 2800 to 3000 cGy in 7 to 10 fractions. Median follow-up was 6 years (range, 2-12). Five-year local control was 75% (95% CI, 34%-91%). Three patients (25%) suffered local relapse at a median of 15 months (range, 5-16 months) after IVRT. All relapses were in patients receiving 2100 cGy and 2 were beyond full dose coverage of IVRT. Subsequent patients receiving higher doses (≥2800 cGy) and full coverage of the vagina have had no local failures. Two of 3 patients who experienced treatment failure were cured with salvage therapy resulting in a 5-year overall survival of 86% (95% CI, 33%-98%).
conclusionsHigh-dose-rate IVRT is an excellent option for local control of vaginal RMS with few long-term risks. A dose of 2800 cGy in 7 fractions prescribed to the entire vagina may be appropriate for optimal prevention of recurrence. Longer follow-up is needed to assess the preservation of ovarian, reproductive, and sexual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.